Becton Dickinson (BDX) is a bio-medical technology company with recent developments in multiple areas. Having named
Michael Feld as the new
President of its Life Sciences Segment, the company has shown growth potential in terms of leadership changes. It appears that large players like
AQR Capital Management LLC and
Lighthouse Investment Partners LLC have altered their position in BDX, with precise actions differing. A noticeable
36% undervaluation of the company has been suggested and it's announced that it will
pay a dividend soon. Critical news includes
BDX acquiring the critical care from Edwards Lifesciences, with the purchase being completed. BDX has faced challenges including a blood culture product delay warning and modifications in short interests and stock positions. Despite this, there is positive sentiment revolving around their
Q3 earnings beating estimates and boosting FY24 expectations. The company completed its acquisition of Critical Care from Edwards Lifesciences and celebrated 75 years of U.S. manufacturing excellence. In addition, Becton Dickinson’s financial leadership changes bring a fresh phase of decision-making to the company.
Becton Dickinson and BDX News Analytics from Wed, 08 Nov 2023 08:00:00 GMT to Sat, 28 Sep 2024 09:37:05 GMT -
